Project Grant R42CA306378
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Foxfield, CO 80016, USA
Similar Awards
- This federal Project Grant award of $205,700 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the Sloan-Kettering Institute for Cancer Research in New York aimed at understanding and overcoming rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies, and to test a novel combination approach to...
- The National Cancer Institute, under the Cancer Treatment Research federal grant program (CFDA 93.395), awarded a $400,000 project grant to Nuago Therapeutics Inc. on June 9, 2025. The grant supports the development of a short RNA therapeutic to treat ovarian cancer. This research aims to develop a novel, targeted cancer therapy that can potentially overcome limitations of existing cancer treatments. The award has a projected completion date of May 31, 2026 and will be conducted at the company's...
- This $375,134 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel approach for reducing the off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize an innate immune response that can be leveraged to limit nanoparticle deposition in healthy tissues, thereby enhancing delivery to tumors and improving the efficacy of chemotherapy. The 5-year project, starting on March 1, 2025,...
- The National Cancer Institute (NCI) awarded a $306,871 Project Grant to Vivere Oncotherapies, Inc. under the Cancer Treatment Research federal grant program (CFDA 93.395) to advance the development of their OV-151 oncolytic virotherapy product for the treatment of colorectal cancer. The project aims to: 1) characterize the delivery properties of the OV-151 clinical vector to tumors, 2) optimize the therapeutic cargo delivered by the vector, and 3) develop an inducible promoter to enhance...
- This $640,583 federal Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Cold Spring Harbor Laboratory to conduct research aimed at enhancing the efficacy of immunotherapy against metastatic colorectal cancer. The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their anti-tumor immunity and improve treatment outcomes for patients with microsatellite stable metastatic colorectal cancer, who typically respond poorly...
- This $393,872 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of Texas Health Science Center at Houston (UTHealth) to develop antibody-drug conjugates (ADCs) that co-target the LGR5 and MET proteins in colorectal cancer. The goal is to overcome tumor heterogeneity and therapy resistance by using two different drug payloads with distinct mechanisms of action. The research will first scale up production...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $406,611 to the University of Texas Health Science Center at Houston (UTHealth) to identify the role and signaling mechanisms of the GPR56 protein in colorectal cancer progression and therapy resistance. The project aims to develop and evaluate novel antibody-drug conjugates and combination therapies targeting GPR56 for the improved treatment of colorectal cancer. Key activities...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $395,724 to PPI Pharmaceuticals LLC to investigate a series of compounds called "Abbapolins" that inhibit the Polo-like Kinase 1 (PLK1) protein, which is a key regulator of cell division and a validated anti-cancer drug target. The project aims to further optimize the Abbapolin leads and evaluate their activity against colorectal cancers, including testing them on a panel of...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support the development of a "Spatial Profiling-Based Immune Hub Perturbation Platform" to improve immunotherapy for colorectal cancer. The $710,361 award to J. David Gladstone Institutes will fund research to create a novel experimental framework to systematically test and prioritize candidate genes and therapies based on their ability to induce effective anti-tumor immune hubs -...
- This federal Project Grant award of $117,018 from the National Cancer Institute's Cancer Research Manpower Program (CFDA 93.398) supports research to investigate the effects of combining polyunsaturated fatty acids (PUFAs) and photosensitizers to enhance the efficacy of chemotherapy in treating metastatic ovarian cancer. The project aims to utilize photodynamic alterations of cell membrane lipids to promote chemotherapy penetration and efficacy in preclinical models of peritoneal metastases. The...